Price$0.41+0.10 (+33.25%)
2026-04-212026-07-24
News · 26 weeks27-86%
2026-02-012026-07-26
Mix1890d
- SEC Filings9(50%)
- Other6(33%)
- Earnings3(17%)
Latest news
25 items- PRMilestone Scientific Launches First Phase of AI Strategy with Pilot Debut of Milo, an AI-enabled Digital Engagement Platform, at ASPN 2026AI-powered Initiative Aims to Enhance Customer Engagement, Accelerate Commercial Execution and Support Long-Term Growth Visit booth #112 in the Sparkle Ballroom at Fontainebleau Miami Beach for a live demonstration of Milo ROSELAND, N.J., July 15, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a medical technology company developing proprietary precision drug delivery and Dynamic Pressure Sensing® technologies for medical and dental applications, today announced the launch of the first phase of its artificial intelligence ("AI") strategy with the introduction of Milo™, the Company's AI-enabled digital engagement platform, at the American Society of Pain and Neuroscience
- PRMilestone Scientific Reports Preliminary 1H 2026 Revenue of ~$5.0M, +9% YoY; Q2 2026 Revenue of ~$2.8M, +21% YoYMedical Segment Momentum Accelerates, Posting 300% Growth Versus Q2 2025 Company to Showcase Technology at American Society of Pain & Neuroscience Conference in Miami Beach, July 16–18, Alongside Board Member and ASPN Co-Founder and Vice Chairman, Dr. Dawood Sayed ROSELAND, N.J., July 01, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced preliminary, unaudited revenue for the second quarter ending June 30, 2026. The Company expects total revenue of approximately $2.8 million for the second quarter of 2026, representing an approximate 21% increase comp
- SECMilestone Scientific Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - MILESTONE SCIENTIFIC INC. (0000855683) (Filer)
- PRMilestone Scientific Strengthens Board to Support Next Phase of GrowthROSELAND, N.J., June 25, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced a series of strategic governance initiatives designed to support the Company’s continued evolution and long-term growth. These actions include strengthening the Board of Directors with two highly experienced independent directors, transitioning Board leadership to support closer strategic execution and aligning with the Company's founder through a restructured agreement that reinforces continuity and future focus. As part of these initiatives, Benedetta I. Casamento has transitio
- SECSEC Form DEF 14A filed by Milestone Scientific Inc.DEF 14A - MILESTONE SCIENTIFIC INC. (0000855683) (Filer)
- SECSEC Form PRER14A filed by Milestone Scientific Inc.PRER14A - MILESTONE SCIENTIFIC INC. (0000855683) (Filer)
- SECSEC Form EFFECT filed by Milestone Scientific Inc.EFFECT - MILESTONE SCIENTIFIC INC. (0000855683) (Filer)
- SECSEC Form 424B1 filed by Milestone Scientific Inc.424B1 - MILESTONE SCIENTIFIC INC. (0000855683) (Filer)
- SECSEC Form PRE 14A filed by Milestone Scientific Inc.PRE 14A - MILESTONE SCIENTIFIC INC. (0000855683) (Filer)
- SECSEC Form S-3 filed by Milestone Scientific Inc.S-3 - MILESTONE SCIENTIFIC INC. (0000855683) (Filer)
- PRMilestone Scientific Highlights Growing Clinical Adoption and Expanding Physician Acceptance of CompuFlo® Across Epidural, Neuromodulation, and Interventional Pain ProceduresROSELAND, N.J., May 27, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments utilizing Dynamic Pressure Sensing™ (DPS) technology, today highlighted the continued growth in clinical adoption and physician acceptance of its CompuFlo® Epidural System following the publication of new peer-reviewed research from the University of Texas Medical Branch (UTMB). The newly published study in Operative Neurosurgery demonstrated that CompuFlo-guided epidural access during spinal cord stimulator (SCS) implantation procedures was associated with significantly lower complication rates compared with conventional loss-of-resistance
- PRMilestone Scientific Reports Financial Results for First Quarter 2026Operating Loss Reduced As Company Advances Toward Profitability Reaffirms Outlook for Double-Digit Revenue Growth in 2026, including Significant Growth in CompuFlo® Sales ROSELAND, N.J., May 14, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provided a business update and announced financial results for the three months ended March 31, 2026. "Our first quarter results reflect continued progress as we execute on the foundation established in 2025," said Eric Hines, Chief Executive Officer of Milestone Scientific. "We delivered meaningful improvements in opera
- SECSEC Form 10-Q filed by Milestone Scientific Inc.10-Q - MILESTONE SCIENTIFIC INC. (0000855683) (Filer)
- PRMilestone Scientific Schedules First Quarter 2026 Financial Results and Business Update Conference CallROSELAND, N.J., May 07, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide objective, pressure-guided precision, today announced that it will host a conference call at 8:30 AM Eastern Time on Thursday, May 14, 2026, to discuss the company's financial results for the first quarter ended March 31, 2026, as well as the company's corporate progress and other developments. The conference call will be available via telephone by dialing toll free 888-506-0062 for U.S. callers or +1 973-528-0011 for international callers and by entering the access code: 950491. A live webcast and replay are available here: htt
- PRMilestone Scientific Expands CompuFlo® Medical Business with Advisor Program and Growing National Clinical AdoptionROSELAND, N.J., May 07, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, today provided an update on the expansion of its CompuFlo® medical business, highlighting increasing physician utilization, expanding clinical engagement, and continued development of its commercial and reimbursement infrastructure. Advisor Program Driving Utilization and Real-World Data Generation Since launching the CompuFlo® Advisor Program in February 2026, the Company has onboarded physician advisors and initiated procedural use across key Medicare Administrative Contractor (MAC) jurisdictions, including Novitas, First Coast Service O
- SECMilestone Scientific Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits8-K - MILESTONE SCIENTIFIC INC. (0000855683) (Filer)
- SECMilestone Scientific Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - MILESTONE SCIENTIFIC INC. (0000855683) (Filer)
- SECAmendment: SEC Form 10-K/A filed by Milestone Scientific Inc.10-K/A - MILESTONE SCIENTIFIC INC. (0000855683) (Filer)
- SECSEC Form D filed by Milestone Scientific Inc.D - MILESTONE SCIENTIFIC INC. (0000855683) (Filer)
- SECMilestone Scientific Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - MILESTONE SCIENTIFIC INC. (0000855683) (Filer)
- PRMilestone Scientific Inc. Completes $2.15 Million Private PlacementROSELAND, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the closing of a $2.15 million private placement of common stock and warrants, and an additional $2.69 million if cash warrants are fully exercised. "Today we strengthened our balance sheet and positioned the company to capitalize on the increasing demand we are seeing across our product platforms," said Eric Hines, Chief Executive Officer of Milestone Scientific. "This financing allows us to build on our progress, scaling investment in sales, inventory and digital marketing, wh
- SECMilestone Scientific Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - MILESTONE SCIENTIFIC INC. (0000855683) (Filer)
- PRMilestone Scientific Reports Financial Results for Fourth Quarter and Full Year 2025Q4 2025 Marks Transition from Restructuring to Growth For 2026, Expects Double-Digit Revenue Growth, 400% Increase in CompuFlo Sales, and Continued Progress Toward Profitability ROSELAND, N.J., March 31, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provided a business update and announced financial results for the year ended December 31, 2025. Eric Hines, Chief Executive Officer of Milestone Scientific commented: "When I joined Milestone in August 2025, we were in the middle of the third quarter following a period without consistent execut
- SECSEC Form 10-K filed by Milestone Scientific Inc.10-K - MILESTONE SCIENTIFIC INC. (0000855683) (Filer)
- PRMilestone Scientific Schedules Fourth Quarter and FY 2025 Financial Results and Business Update Conference CallROSELAND, N.J., March 26, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide objective, pressure-guided precision, today announced that it will host a conference call at 8:30 AM Eastern Time on Wednesday, April 1, 2026, to discuss the company's financial results for the fourth quarter and full year ended December 31, 2025, as well as the company's corporate progress and other developments. The conference call will be available via telephone by dialing toll free 888-506-0062 for U.S. callers or +1 973-528-0011 for international callers and by entering the access code: 875878. A webcast and replay of the
MLSS FAQ
6 questionsWhat does Milestone Scientific Inc. do?
Milestone Scientific, Inc. develops computer-controlled anesthetic delivery devices for the medical and dental markets in the United States, China, and internationally. The company operates in two segments, Dental and Medical. Its products include CompuDent System that are used to control the flow rate of the anesthesia during the injection, which allows virtually painless injections for various dental procedures, including routine fillings, implants, root canals, and crowns. The company also offers CompuFlo, a computer-controlled drug delivery system for the painless delivery of drugs...Where does MLSS stock trade?
Milestone Scientific Inc. (MLSS) is listed on AMEX.What sector and industry is MLSS in?
Milestone Scientific Inc. operates in the Health Care sector, Industrial Specialties industry.When did Milestone Scientific Inc. go public?
Milestone Scientific Inc. (MLSS) completed its IPO in 2015.What companies are similar to MLSS?
Notable peers in the same industry include ISRG (Intuitive Surgical Inc.), EW (Edwards Lifesciences Corporation), STE (STERIS plc (Ireland)), ZBH (Zimmer Biomet Holdings Inc.), MAS (Masco Corporation). Compare MLSS side-by-side with any of them on Quantisnow.How can I track MLSS on Quantisnow?
Quantisnow aggregates Milestone Scientific Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MLSS to receive live email and push alerts on every new disclosure.